KINNATE BIOPHARMA INC (KNTE)
US49705R1059 - Common Stock
Overall KNTE gets a fundamental rating of 2 out of 10. We evaluated KNTE against 572 industry peers in the Biotechnology industry. While KNTE has a great health rating, there are worries on its profitability. KNTE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
KNTE had negative earnings in the past year.
KNTE had a negative operating cash flow in the past year.
KNTE had negative earnings in each of the past 5 years.
KNTE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -64.89%, KNTE is not doing good in the industry: 62.35% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -70.70%, KNTE is in line with its industry, outperforming 56.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| ROIC | N/A |
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for KNTE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for KNTE has been increased compared to 1 year ago.
KNTE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KNTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
KNTE has an Altman-Z score of 1.00. This is a bad value and indicates that KNTE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KNTE (1.00) is better than 64.57% of its industry peers.
KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.
KNTE has a Current ratio of 13.19. This is amongst the best in the industry. KNTE outperforms 86.88% of its industry peers.
A Quick Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.
KNTE's Quick ratio of 13.19 is amongst the best of the industry. KNTE outperforms 87.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.19 | ||
| Quick Ratio | 13.19 |
3. Growth
3.1 Past
KNTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.68%, which is quite good.
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, KNTE will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
KNTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KNTE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KNTE's earnings are expected to grow with 13.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.83%
EPS Next 3Y13.35%
5. Dividend
5.1 Amount
No dividends for KNTE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KINNATE BIOPHARMA INC
NASDAQ:KNTE (4/2/2024, 8:25:40 PM)
After market: 2.65 0 (0%)2.65
-0.01 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.91%
Inst Owner Change0%
Ins Owners6.99%
Ins Owner Change0%
Market Cap125.00M
Analysts78
Price Target2.41 (-9.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.27%
Min EPS beat(2)5.59%
Max EPS beat(2)16.95%
EPS beat(4)4
Avg EPS beat(4)8.9%
Min EPS beat(4)1.96%
Max EPS beat(4)16.95%
EPS beat(8)7
Avg EPS beat(8)3.8%
EPS beat(12)7
Avg EPS beat(12)0.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.35%
PT rev (3m)-12.47%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)5.3%
EPS NY rev (1m)0%
EPS NY rev (3m)9.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.78 | ||
| P/tB | 0.78 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.42
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS3.38
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.19 | ||
| Quick Ratio | 13.19 | ||
| Altman-Z | 1 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)365%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.37%
OCF growth 3YN/A
OCF growth 5YN/A